Vitamin D prevents podocyte injury via regulation of macrophage M1/M2 phenotype in diabetic nephropathy rats

Endocrinology (United States)

Volumn 155, Issue 12, 2014, Pages 4939-4950

  Zhang, Xiao Liang ^a   Guo, Yin Feng ^a   Song, Zhi Xia ^a   Zhou, Min ^a  

^a MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; CD163 ANTIGEN; CELL SURFACE RECEPTOR; DIFFERENTIATION ANTIGEN; GLUCOSE BLOOD LEVEL; INDUCIBLE NITRIC OXIDE SYNTHASE; LEUKOCYTE ANTIGEN; MEMBRANE PROTEIN; NEPHRIN; NOS2 PROTEIN, RAT; PODOCIN; SIGNAL PEPTIDE; VITAMIN;

ANIMAL; BODY WEIGHT; DIABETIC NEPHROPATHIES; DRUG EFFECTS; DRUG SCREENING; GLOMERULUS; GLUCOSE BLOOD LEVEL; IMMUNOLOGY; KIDNEY FUNCTION TEST; MACROPHAGE; MALE; METABOLISM; PHENOTYPE; PODOCYTE; RANDOMIZATION; RAT; SPRAGUE DAWLEY RAT;

ANIMALS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; BLOOD GLUCOSE; BODY WEIGHT; CALCITRIOL; DIABETIC NEPHROPATHIES; DRUG EVALUATION, PRECLINICAL; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY FUNCTION TESTS; KIDNEY GLOMERULUS; MACROPHAGES; MALE; MEMBRANE PROTEINS; NITRIC OXIDE SYNTHASE TYPE II; PHENOTYPE; PODOCYTES; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CELL SURFACE; VITAMINS;

EID: 84914101858     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2014-1020     Document Type: Article

References (45)

1. Jefferson JA, Shankland SJ, Pichler RH. Proteinuria in diabetic kidney disease: a mechanistic viewpoint. Kidney Int. 2008;74(1):22-36.
2. Mathieson PW. The podocyte as a target for therapies - new and old. Nat Rev Nephrol. 2012;8(1):52-56.
3. Nelson CL, Karschimkus CS, Dragicevic G, et al. Systemic and vascular inflammation is elevated in early IgA and type 1 diabetic nephropathies and relates to vascular disease risk factors and renal function. Nephrol Dial Transplant. 2005;20(11):2420-2426.
4. Nguyen D, Ping F, Mu W, Hill P, Atkins RC, Chadban SJ. Macrophage accumulation in human progressive diabetic nephropathy. Nephrology (Carlton). 2006;11(3):226-231.
5. Chow F, Ozols E, Nikolic-Paterson DJ, Atkins RC, Tesch GH. Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury. Kidney Int. 2004;65(1):116-128.
6. Takano Y, Yamauchi K, Hayakawa K, et al. Transcriptional suppression of nephrin in podocytes by macrophages: roles of inflammatory cytokines and involvement of the PI3K/Akt pathway. FEBS Lett. 2007;581(3):421-426.
7. Zhang XL, Selbi W, de la Motte C, Hascall V, Phillips A. Renal proximal tubular epithelial cell transforming growth factor-beta1 generation and monocyte binding. Am J Pathol. 2004;165(3):763-773.
8. Lan HY. Diverse roles of TGF-β/Smads in renal fibrosis and inflammation. Int J Biol Sci. 2011;7(7):1056-1067.
9. Wang Y, Wang YP, Zheng G, et al. Ex vivo programmed macrophages ameliorate experimental chronic inflammatory renal disease. Kidney Int. 2007;72(3):290-299.
10. Ricardo SD, van Goor H, Eddy AA. Macrophage diversity in renal injury and repair. J Clin Invest. 2008;118(11):3522-3530.
11. Endo I, Inoue D, Mitsui T, et al. Deletion of vitamin D receptor gene in mice results in abnormal skeletal muscle development with deregulated expression of myoregulatory transcription factors. Endocrinology. 2003;144(12):5138-5144.
12. Lagishetty V, Misharin AV, Liu NQ, et al. Vitamin D deficiency in mice impairs colonic antibacterial activity and predisposes to colitis. Endocrinology. 2010;151(6):2423-2432.
13. Levin A, Li YC. Vitamin D and its analogues: do they protect against cardiovascular disease in patients with kidney disease? Kidney Int. 2005;68(5):1973-1981.
14. Rossing P, Joergensen C. Diabetes: Effect of vitamin D on diabetic kidney disease in T1DM. Nat Rev Endocrinol. 2013;9(1):6-7.
15. Kim MJ, Frankel AH, Donaldson M, et al. Oral cholecalciferol decreases albuminuria and urinary TGF-β1 in patients with type 2 diabetic nephropathy on established renin-angiotensin-aldosterone system inhibition. Kidney Int. 2011;80(8):851-860.
16. Li YC. Podocytes as target of vitamin D. Curr Diabetes Rev. 2011;7(1):35-40.
17. He W, Kang YS, Dai C, Liu Y. Blockade of Wnt/β-catenin signaling by paricalcitol ameliorates proteinuria and kidney injury. J Am Soc Nephrol. 2011;22(1):90-103.
18. Li X, Zheng W, Li YC. Altered gene expression profile in the kidney of vitamin D receptor knockout mice. J Cell Biochem. 2003;89(4):709-719.
19. Odegaard JI, Ricardo-Gonzalez RR, Goforth MH, et al. Macro-phage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature. 2007;447(7148):1116-1120.
20. Dunlop TW, Väisänen S, Frank C, Molnár F, Sinkkonen L, Carlberg C. The human peroxisome proliferator-activated receptor delta gene is a primary target of 1alpha,25-dihydroxyvitamin D3 and its nuclear receptor. J Mol Biol. 2005;349(2):248-260.
21. Sun H, Yuan Y, Sun ZL. Cholesterol contributes to diabetic nephropathy through SCAP-SREBP-2 pathway. Int J Endocrinol. 2013;2013:592576.
22. Sugimoto H, LeBleu VS, Bosukonda D, et al. Activin-like kinase 3 is important for kidney regeneration and reversal of fibrosis. Nat Med. 2012;18(3):396-404.
23. Damasiewicz MJ, Magliano DJ, Daly RM, et al. Serum 25-hydoi: droxyvitamin D deficiency and the 5-year incidence of CKD. Am J Kidney Dis. 2013;62(1):58-66.
24. Melamed ML, Astor B, Michos ED, Hostetter TH,Powe NR, Muntner P. 25-Hydroxyvitamin D levels, race, and the progression of kidney disease. J Am Soc Nephrol. 2009;20(12):2631-2639.
25. Pilz S, Iodice S, Zittermann A, Grant WB, Gandini S. Vitamin D status and mortality risk in CKD: a meta-analysis of prospective studies. Am J Kidney Dis. 2011;58(3):374-382.
26. Rouached M, El Kadiri Boutchich S, Al Rifai AM, Garabédian M, Fournier A. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 2008;74(3):389-390.
27. Li YC. Vitamin D: roles in renal and cardiovascular protection. Curr Opin Nephrol Hypertens. 2012;21(1):72-79.
28. Alborzi P, Patel NA, Peterson C, et al. Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized dou-ble-blind pilot trial. Hypertension. 2008;52(2):249-255.
29. Mizobuchi M, Morrissey J, Finch JL, et al. Combination therapy with an angiotensin-converting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats. J Am Soc Nephrol. 2007;18(6):1796-1806.
30. Ito I, Waku T, Aoki M, et al. A nonclassical vitamin D receptor pathway suppresses renal fibrosis. J Clin Invest. 2013;123(11):4579-4594.
31. Freundlich M, Quiroz Y, Zhang Z, et al. Suppression of renin-angiotensin gene expression in the kidney by paricalcitol. Kidney Int. 2008;74(11):1394-1402.
32. Park JW, Bae EH, Kim IJ, et al. Paricalcitol attenuates cyclosporine-induced kidney injury in rats. Kidney Int. 2010;77(12):1076-1085.
33. Deb DK, Wang Y, Zhang Z, et al. Molecular mechanism underlying 1, 25-dihydroxyvitamin D regulation of nephrin gene expression. J Biol Chem. 2011;286(37):32011-32017.
34. Wilson HM, Walbaum D, Rees AJ. Macrophages and the kidney. Curr Opin Nephrol Hypertens. 2004;13(3):285-290.
35. Eardley KS, Zehnder D, Quinkler M, et al. The relationship between albuminuria, MCP-1/CCL2, and interstitial macrophages in chronic kidney disease. Kidney Int. 2006;69(7):1189-1197.
36. Ogawa D, Shikata K, Matsuda M, et al. Preventive effect of sulphated colominic acid on P-selectin-dependent infiltration of macrophages in experimentally induced crescentic glomerulonephritis. Clin Exp Immunol. 2002;129(1):43-53.
37. Cao Q, Wang C, Zheng D, et al. IL-25 induces M2 macrophages and reduces renal injury in proteinuric kidney disease. J Am Soc Nephrol. 2011;22(7):1229-1239.
38. Zhang X, Mosser DM. Macrophage activation by endogenous danger signals. J Pathol. 2008;214(2):161-178.
39. Szekanecz Z, Koch AE. Macrophages and their products in rheumatoid arthritis. Curr Opin Rheumatol. 2007;19(3):289-295.
40. Ryu M, Kulkarni OP, Radomska E, Miosge N, Gross O, Anders HJ. Bacterial CpG-DNA accelerates Alport glomerulosclerosis by inducing an M1 macrophage phenotype and tumor necrosis factor-α-mediated podocyte loss. Kidney Int. 2011;79(2):189-198.
41. Ikezumi Y, Suzuki T, Karasawa T, Kawachi H, Nikolic-Paterson DJ, Uchiyama M. Activated macrophages down-regulate podocyte nephrin and podocin expression via stress-activated protein kinases. Biochem Biophys Res Commun. 2008;376(4):706-711.
42. Duffield JS. Macrophages in kidney repair and regeneration. J Am Soc Nephrol. 2011;22(2):199-201.
43. Nishida M, Okumura Y, Fujimoto S, Shiraishi I, Itoi T, Hamaoka K. Adoptive transfer of macrophages ameliorates renal fibrosis in mice. Biochem Biophys Res Commun. 2005;332(1):11-16.
44. Lee S, Huen S, Nishio H, et al. Distinct macrophage phenotypes contribute to kidney injury and repair. J Am Soc Nephrol. 2011;22(2):317-326.
45. Ndisang JF, Jadhav A. Hemin therapy improves kidney function in male streptozotocin-induced diabetic rats: role of the heme oxygenase/atrial natriuretic peptide/adiponectin axis. Endocrinology. 2014;155(1):215-229.